ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / PODD / financials
GMED (72) BAX (51) PEN (57) SOLV (45) ⌘ Pro Terminal β†’

Insulet Corporation (PODD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$149.68 -1.85% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $149.54

Insulet Corporation (PODD) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (72% profit margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY β€’ 69.0% hit rate) β†’
ROARABLE B β€’ BUY Cap $10.58B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PODD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PODD compare to GMED and BAX in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PODD?
β–Ό

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $149.55 (-0.09%)🧬 Cannibal Buyback (-2.36% YoY Shares)βš™οΈ Cash Engine: 19/20 (A+) β€’ 13.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY β€’ 69.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510073
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ Β· Rk C+
Cash (19)Whales (11)SEC (18)Macro (9)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+6.7% Base Target
$373 Bull$160 Base$123 Bear
πŸ“¬ FREE PODD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PODD)Realized 20D OHLCV Swing Band: Β±6.2%
Deterministic 5-Pillar Attribution (73/100 Composite)
πŸ” WHY PODD SCORES 73/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+19/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($377.7M FCF) & 71.6% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 5.72 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–Ό #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (66) create a -11 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
65
Grade C+$138.13+3.3% Next Q
Q2 (-2Q)
68
Grade B-$142.64+5% Next Q
Q3 (-1Q)
70
Grade B$149.83-0.1% Next Q
Current
73
Grade B$149.68+7.1% Hist 90D Ξ±
Trajectory: C+ (65) β†’ B (73)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the PODD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 73/100 (B) score, PODD faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 43x earningsβ€”high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($141.14) or 200D SMA ($177.45) invalidates the momentum regime and cuts Target Base ($159.78) toward Bear Floor ($122.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PODDβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPODD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 73%NO 27%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How PODD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$377.7M (13.9% FCF Margin)
Revenue$2.71BGross Profit $1.94B (71.6%)Cost of Sales $768.2MOp Profit $473.8M (17.5%)OpEx (R&D/SG&A) $1.47BNet Profit$247.1M (9.1%)Tax/Other $226.7M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $1.70B
FY24
Rev $2.07B
FY25
Rev $2.71B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$2.71B71.6%17.5%$247.1M$377.7M19.5%
FY 2024$2.07B69.8%14.9%$418.3M$305.3M14.2%
FY 2023$1.70B71.6%13%$206.3M$69.3M4.9%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PODD)

  • βœ“Walkthrough of PODD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PODD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.67%β–² ASCENDING TRIANGLE
2026-11-02O $148.9H $152.5L $148.9C $149.7VOL 1.30M
RES: $154.9SUP: $128.9SMA50: $141.1SMA200: $177.5
$292.3$247.4$202.4$157.4$112.4RES $154.9SUP $128.9$149.72026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PODD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PODD Butterfly Map β†’ + Track PODD β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
32.2%/yr Implied 5Y Growth

vs. +30.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PODD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PODD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PODD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PODD)

Health Care Rank #57 of 1016 βš”οΈ GMED vs PODD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PODD vs. GMED, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Insulet Corporation (PODD) ranks #57 by composite RQD confidence (73/100, grade B) and #106 by equity capitalization ($10.58B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PODD ACTIVE
Insulet Corporation
B 73/100 42.8x 71.6% 20.4% -1.85% $10.58B Benchmark Subject
GMED
Globus Medical Inc.
B 72/100 20.7x 67.4% 8.7% -5.86% $11.13B /gmed-vs-podd β†’
BAX
Baxter International Inc.
D 51/100 β€” 30.1% -2.4% -2.13% $12.15B /bax-vs-podd β†’
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% -0.94% $12.68B /pen-vs-podd β†’
SOLV
Solventum Corporation
D 45/100 9.1x 53.5% 18.7% -2.67% $14.22B /solv-vs-podd β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001145197

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insulet Corporation (PODD) reported GAAP revenue of $2.71B (+30.7% vs. FY2024 revenue of $2.07B , and +59.6% cumulative change since FY2023) , GAAP net income of $247.1M, operating cash flow of $569.3M, and free cash flow of $377.7M (+23.7% YoY). On the balance sheet, PODD closed FY2025 with $3.19B in total assets against $753.8M in total debt (Altman Z-Score: 5.72, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.71B $247.1M $569.3M $377.7M $3.19B $753.8M
FY2024 (FY) 2024-12-31 $2.07B $418.3M $430.2M $305.3M $3.09B $844.2M
FY2023 (FY) 2023-12-31 $1.70B $206.3M $145.7M $69.3M $5.82B $1.36B

3. PODD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.

How does PODD compare to GMED and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PODD?

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PODD trading relative to its 50-day, 200-day, and 52-week technical levels?

PODD last traded at $149.68 (-1.85% on volume of 1,090,433 shares), positioning the stock +6.05% above its 50-day simple moving average ($141.14) and -15.65% below its 200-day simple moving average ($177.45). Across its 52-week range of $126.40 to $354.88, PODD sits at the 10.2% percentile with a 14-day RSI of 66.0 (BULLISH MOMENTUM) and an implied next-earnings move of Β±6.2% ($140.40 to $158.96).

PODD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is Insulet Corporation (PODD)?

In FY 2025 (10-K), PODD converted $2.7B of revenue into a 71.6% gross margin, 17.5% operating margin, and $377.7M in free cash flow (13.9% FCF margin).

Direct Sub-Reports: PODD RQD Cockpit PODD 12M Forecast PODD Earnings & Move PODD Dividends & DRIP PODD Insiders & 13F PODD Whale Options PODD Profit Sankey PODD News & Why
ROARABLE RATING BRIEF β€’ RQD 73/100 (B) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

PODD β€” Insulet Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:22Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PODD scores 73 out of 100, graded B and labeled "Roarable Buy β€” Good Risk/Reward." The five pillars are: Fundamental Cash Engine 19/20 (ROIC 20.4%; FCF yield 3.57%), Whale 13F Flow 11/20 (institutional accumulation and options positioning), Insider Conviction 16/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 0.99; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 5.72; Piotroski F 8/9; Debt/Equity 0.46).

The strongest pillar is the cash engine, which indicates the rating's fundamental case rests mainly on returns on invested capital and free-cash-flow generation rather than on valuation. The forensic balance-sheet pillar is also strong. The weakest pillar is macro regime fit, where the near-market beta suggests the stock tracks broader market movement rather than diverging from it. Whale flow is moderate. Upside drivers in this framework are continued cash generation and balance-sheet strength; valuation tradeoffs are visible in the elevated trailing P/E relative to the forward P/E, and the 3.57% FCF yield should be weighed against those multiples. This is an analytical summary of the rating's components, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
152.5$10.58B42.83617.13.560%0.99$126.4 - $354.8820.4%

Business

Insulet Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the company profile. Not available in source data for specific products, customers, or revenue-generation detail. The source data reports gross margin of 71.6%, operating margin of 17.5%, and net margin of 9.1% per the market data section.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2708.1M$473.8M$247.1MN/A$377.7MN/A$753.8M
FY 2024$2071.6M$308.9M$418.3MN/A$305.3MN/A$844.2M
FY 2023$1697.1M$220.1M$206.3MN/A$69.3MN/A$1361.2M

Reported revenue rose across the three periods, from $1697.1M in FY 2023 to $2708.1M in FY 2025, and debt declined from $1361.2M to $753.8M over the same span. Net income was $418.3M in FY 2024 and $247.1M in FY 2025. Per the market data, ROIC is 20.4% and net margin is 9.1%. Per the Roarable RQD forensic pillar, the Altman Z-Score is 5.72, the Piotroski F-Score is 8/9, and Debt/Equity is 0.46, which together describe a balance sheet the source data characterizes as strong. Cash balances are not available in source data.

Open Questions

  • What are the reported cash balances, since the financials section lists cash as N/A for every period?
  • What are the reported EPS figures, since the financials section lists EPS as N/A for every period?
  • What is the analyst consensus rating and price target, given that analyst data is absent?
  • What is the reported supply-chain exposure, given the butterfly graph shows no links?
  • How do the 52-week high and low ($354.88 and $126.4) relate to the drivers behind the current price of $152.5?

PODD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Insulet Corporation (PODD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PODD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PODD Bull vs. Bear Conversation Board β€” What's Your Call at $149.68?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PODD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PODD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $179.95 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is PODD (B β€’ RQD 73/100) a Buy at $152.50?

Welcome to the PODD (Insulet Corporation) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy β€” Good Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (20.4% ROIC), while bears focus on valuation multiple compression (42.8x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $125.05 (-18.0%)
Spot @ $152.50

Pump the brakes on PODD β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PODD, but look at what you are paying: 42.8x trailing P/E with 71.6% gross margins. Unless Insulet Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $176.90 (+16.0%)
Spot @ $152.50

PODD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PODD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $152.50 (52-wk range $126.40 - $354.88), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%